Cephalon’s Nuvigil User-Fee Date Extended
This article was originally published in The Pink Sheet Daily
Executive Summary
The company still expects to bring the excessive sleepiness therapy to market by mid-2006.
You may also be interested in...
Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials
Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.
Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials
Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.
Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year
Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.